Matches in Nanopublications for { ?s ?p "[Despite 17% to 39% of all BRCA mutation carriers having a mutation in BRCA2, no prospective study to date has evaluated the efficacy of RRSO for the prevention of breast and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritoneal) cancer when BRCA2 mutation carriers are analyzed separately from BRCA1 mutation carriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[Despite 17% to 39% of all BRCA mutation carriers having a mutation in BRCA2, no prospective study to date has evaluated the efficacy of RRSO for the prevention of breast and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritoneal) cancer when BRCA2 mutation carriers are analyzed separately from BRCA1 mutation carriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP273223.RAQxNDh2_sLnQCjIhuAfGVzEdsakrTZCHzhqynbq-PxuU130_assertion description "[Despite 17% to 39% of all BRCA mutation carriers having a mutation in BRCA2, no prospective study to date has evaluated the efficacy of RRSO for the prevention of breast and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritoneal) cancer when BRCA2 mutation carriers are analyzed separately from BRCA1 mutation carriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP273223.RAQxNDh2_sLnQCjIhuAfGVzEdsakrTZCHzhqynbq-PxuU130_provenance.
- NP837171.RA3yTgoRVZ9YxYNM51Z0domAaV59XC-vqtOEF3JS363uQ130_assertion description "[Despite 17% to 39% of all BRCA mutation carriers having a mutation in BRCA2, no prospective study to date has evaluated the efficacy of RRSO for the prevention of breast and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritoneal) cancer when BRCA2 mutation carriers are analyzed separately from BRCA1 mutation carriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP837171.RA3yTgoRVZ9YxYNM51Z0domAaV59XC-vqtOEF3JS363uQ130_provenance.
- NP655006.RAQj7PKkTlxIpcSsd3W_wkxDFhucmJCoxgj90LYy6csZs130_assertion description "[Despite 17% to 39% of all BRCA mutation carriers having a mutation in BRCA2, no prospective study to date has evaluated the efficacy of RRSO for the prevention of breast and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritoneal) cancer when BRCA2 mutation carriers are analyzed separately from BRCA1 mutation carriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP655006.RAQj7PKkTlxIpcSsd3W_wkxDFhucmJCoxgj90LYy6csZs130_provenance.